Antithrombotic Management After Intracranial Hemorrhage.
Curr Treat Options Cardiovasc Med
; 21(12): 88, 2019 Dec 10.
Article
en En
| MEDLINE
| ID: mdl-31823078
ABSTRACT
PURPOSE OF REVIEW Intracranial hemorrhage remains one of the most feared acute neurological emergencies. However, apart from the acute management, secondary risk factor management and prevention of ischemic events remains ambiguous. We present a thorough review of the current data available regarding management of antithrombotics after intracranial hemorrhage. RECENT FINDINGS:
The most robust evidence comes from the investigators of the RESTART trial which reassured the safety of resuming antiplatelet therapy after ICH, namely in patients with prior indication and treatment with antithrombotics. We conclude that based on available data, the risk of recurrent ICH is probably too small to exceed the found benefits of antiplatelet therapy in the secondary prevention of ischemic vascular disease.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Risk_factors_studies
Idioma:
En
Revista:
Curr Treat Options Cardiovasc Med
Año:
2019
Tipo del documento:
Article
País de afiliación:
Estados Unidos